Abstract
Rituximab Induced Neutropenia in a Patient with Bullous Pemphigoid
Rituximab, a chimeric monoclonal antibody against the CD20 B-cell antigen, is used to treat B-cell malignancies, rheumatoid arthritis, and autoimmune blistering diseases. Adverse events seen with rituximab include infusion reactions, infections, and late or early-onset neutropenia. Specifically, neutropenia is classified as grade III, an absolute neutrophil count (ANC) of 0.5-1.5 x 109/L, or grade IV, an ANC less than 0.5 x 109/L. In this case, we present a bullous pemphigoid (BP) patient with grade IV rituximabinduced neutropenia and safe re-treatment after two years.
Author(s):
Hasan Khosravi, Maryam Abdollahi, Mehrnoosh Badakhsh, Tahereh Soori, Masoud Jafari, Gordon Bae, Maryam Daneshpazhooh
Abstract | Full-Text | PDF
Share this
30+ Million Readerbase
Archives of Medicine peer review process verified at publons
Abstracted/Indexed in
- Google Scholar
- Genamics JournalSeek
- China National Knowledge Infrastructure (CNKI)
- Directory of Research Journal Indexing (DRJI)
- WorldCat
- Proquest Summons
- Publons
- Geneva Foundation for Medical Education and Research
- Secret Search Engine Labs
- Euro Pub
Open Access Journals
- Aquaculture & Veterinary Science
- Chemistry & Chemical Sciences
- Clinical Sciences
- Engineering
- General Science
- Genetics & Molecular Biology
- Health Care & Nursing
- Immunology & Microbiology
- Materials Science
- Mathematics & Physics
- Medical Sciences
- Neurology & Psychiatry
- Oncology & Cancer Science
- Pharmaceutical Sciences